Updated best practice statements regarding sodium-glucose cotransporter 2 inhibitors and serum potassium levels

Updated best practice statements regarding sodium-glucose cotransporter 2 inhibitors and serum potassium levels Lauren G Pamulapati, PharmD, BCACP, Lauren G Pamulapati, PharmD, BCACP Department of Pharmacotherapy and Outcomes Science Virginia Commonwealth University School of PharmacyRichmond, VA, USA lgpamulapati@vcu.edu Search for other works by this author on: Oxford Academic Google Scholar Charmaine D Rochester-Eyeguokan, PharmD, BCACP, CDCES, Charmaine D Rochester-Eyeguokan, PharmD, BCACP, CDCES Department of Pharmacy Practice and Science University of Maryland School of PharmacyBaltimore, MD, USA Search for other works by this author on: Oxford Academic Google Scholar Kathleen J Pincus, PharmD, BCPS, BCACP Kathleen J Pincus, PharmD, BCPS, BCACP Department of Pharmacy Practice and Science University of Maryland School of PharmacyBaltimore, MD, USA Search for other works by this author on: Oxford Academic Google Scholar American Journal of Health-System Pharmacy, Volume 78, Issue 15, 1 August 2021, Pages 1369–1370, https://doi.org/10.1093/ajhp/zxab124 Published: 25 March 2021 Article history Published: 25 March 2021 Corrected and typeset: 19 April 2021